Read by QxMD icon Read


Nicholas Bercovici, Kristen Russomanno, Frank Santoro, Christopher Scola, Michael Murphy, Zendee Elaba
Injection drug abuse (IDA) is known to cause a spectrum of systemic and cutaneous complications. Despite the increasing incidence of IDA around the world, there is a paucity of literature discussing cutaneous complications from a dermatopathologic perspective. We present a case of a 35-year-old male with a complex medical history of Von Willebrand disease, Beçhet disease and diverticular disease. Following a sigmoidectomy/colostomy for diverticular perforation, he presented with fever and an indurated right arm displaying livedoid purpura...
May 2018: Journal of Cutaneous Pathology
(no author information available yet)
A new study has found no evidence of a link between anti-nausea drug Zofran, also known as ondansetron, to an increased risk of having a child with birth defects.
June 1, 2016: Nursing Standard
Ajul Shah, Megan Rowlands, Naveen Krishnan, Anup Patel, Anke Ott-Young
BACKGROUND: Traditionally, narcotics have been used for analgesia after breast surgery. However, these agents have unpleasant side effects. Intercostal nerve blockade is an alternative technique to improve postoperative pain. In this study, the authors investigate outcomes in patients who receive thoracic intercostal nerve blocks for implant-based breast reconstruction. METHODS: A retrospective chart review was performed. The operative technique for breast reconstruction and administration of nerve blocks is detailed...
November 2015: Plastic and Reconstructive Surgery
Eric Dadey
Oral formulations of ondansetron are used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. An oral soluble film formulation of ondansetron (OND OSF) was developed using MonoSol Rx's proprietary PharmFilm technology and was formulated to dissolve rapidly on the tongue, without the need for water. This product provides an oral antiemetic treatment option for patients who experience difficulty swallowing. The purpose of this study was to compare the bioequivalence of OND OSF 8 mg (ZUPLENZ, Monosol Rx, Warren, NJ) with ondansetron orally disintegrating tablets (OND ODT) 8 mg (ZOFRAN, GlaxoSmithKline, Research Triangle Park)...
March 2015: American Journal of Therapeutics
Bengt Danielsson, Birgitta Norstedt Wikner, Bengt Källén
The study investigates teratogenic risks with ondansetron (Zofran(®)). Data from the Swedish Medical Birth Register combined with the Swedish Register of Prescribed Drugs were used to identify 1349 infants born of women who had taken ondansetron in early pregnancy, 1998-2012. Presence of congenital malformations in the offspring was identified with three national health registers. In a Mantel-Haenszel analysis adjustment was made for year of delivery, maternal age, parity, smoking in early pregnancy and pre-pregnancy body mass index...
December 2014: Reproductive Toxicology
I-H Baek, B-Y Lee, J Kang, K-I Kwon
Ondansetron is a potent antiemetic drug that has been commonly used to treat acute and chemotherapy-induced nausea and vomiting (CINV) in dogs. The aim of this study was to perform a pharmacokinetic analysis of ondansetron in dogs following oral administration of a single dose. A single 8-mg oral dose of ondansetron (Zofran(®) ) was administered to beagles (n = 18), and the plasma concentrations of ondansetron were measured by liquid chromatography-tandem mass spectrometry. The data were analyzed by modeling approaches using ADAPT5, and model discrimination was determined by the likelihood-ratio test...
April 2015: Journal of Veterinary Pharmacology and Therapeutics
P J Rudzki, M Kaza, A Leś, E Gilant, H Ksycińska, K Serafin-Byczak, M Troć, J Raszek, E Piątkowska-Chabuda, M Skowrońska-Smolak, A Tarasiuk, E Wilkowska, T Łazowski
The aim of the study was to investigate the bioequivalence of a generic product of 8 mg film-coated tablets (test) to the branded product (reference) at the same strength in order to apply for regulatory approval. The secondary objective of the study was to compare the tolerability of both products. A double blinded, randomized, cross-over, 2-period, comparative study was conducted in healthy Caucasian volunteers under fasting conditions. A single oral dose administration of the test or reference product was followed by a 7-day wash-out period...
April 2014: Drug Research
S N Tenjarla, E S Ward, J L Fox
The objective of this study was to determine the feasibility and develop a formulation for an extemporaneously prepared ondansetron suppository form Zofran 8-mg tablets. The stability of the formulation over 28 days of refrigerated storage and the initial and poststorage drug-release profiles were evaluated. The ondansetron flux in an in vitro model (a rabbit rectal membrane) from each formulation was determined. Suppositories containing 8 or 16 mg ondansetron were made using commercially available hydrophobic and hydrophilic suppository bases...
January 1998: International Journal of Pharmaceutical Compounding
N J Spencer, S J Nicholas, T C Sia, V Staikopoulos, M Kyloh, E A Beckett
BACKGROUND: 5-HT3 antagonists, such as ondansetron (Zofran), retard colonic transit and provide effective relief of symptoms of chronic diarrhea and diarrhea-predominant irritable bowel syndrome (IBS), but the mechanism by which ondansetron retards transit is unclear. What is clear is that the frequency of colonic migrating motor complexes (CMMCs) is reduced by ondansetron, which could account for reduced transit. Our aim was to determine whether an acute depletion of 5-HT from enteric neurons would inhibit spontaneous CMMCs; and determine whether the sensitivity of ondansetron to reduce CMMC frequency would change in a 5-HT-depleted preparation...
August 2013: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
(no author information available yet)
No abstract text is available yet for this article.
December 24, 2012: Medical Letter on Drugs and Therapeutics
Kevin T Collopy, Michael Curtis, Scott R Snyder
Sarah and Michael were able to obtain their patient's blood pressure and heart rate while she was lying in bed as her blood pressure changed from 110/84 to 92/60 and her heart rate increased from 94 to 112 beats per minute. In speaking with her, they learned she was trying to break herself of long-standing alcoholism and had not had a drink in over a week. She had been taking aspirin for her "pains all over." They secured her to their cot in a position of comfort and Sarah established an IV, initiated a fluid bolus of normal saline and administered Zofran to control the patient's nausea and vomiting...
April 2011: EMS World
Allison C Bennett, Tania M Vila
OBJECTIVE: To evaluate the efficacy of ondansetron for the treatment of schizophrenia. DATA SOURCES: Searches of MEDLINE (1950-March 2010) and Google Scholar were performed. Key search terms included ondansetron, Zofran, serotonin antagonists, 5-HT(3) serotonin receptor, and schizophrenia. STUDY SELECTION AND DATA EXTRACTION: All articles published in English identified from the data sources were evaluated. All studies and case reports evaluating ondansetron for the treatment of schizophrenia were reviewed...
July 2010: Annals of Pharmacotherapy
Valentina Reiner, Nadia Giarratana, Nunzia Ceppi Monti, Armin Breitenbach, Peter Klaffenbach
The aim of the research was to assess the bioequivalence between Rapidfilm, a new patented delivery system, versus the traditional orodispersible tablet (ODT). A randomized, two-way, single dose, crossover, bioequivalence study was conducted in 24 fasting, healthy volunteers with two formulations of ondansetron (Ondansetron Rapidfilm vs. Zofran Zydis Lingual ODT by GlaxoSmithKline GmbH & Co. KG). Plasma samples were analysed by a validated LC-MS/MS method during a collection period of 24 h post-dosing. The analysis of variance (ANOVA) on the targeted pharmacokinetic parameters did not show any significant difference between the two formulations and 90% confidence intervals (CIs) fell within the common acceptance range of 80-125%, satisfying the bioequivalence criteria...
June 30, 2010: International Journal of Pharmaceutics
Fritz Fuller, Geoff North
The causes of N&V can be medications; abdominal, infectious, endocrine and CNS illnesses; environmental and toxicological conditions and ischemia. There are several interventions that EMS providers can use to minimize patient's N&V, including oxygen and medications such as promethazine (Phenergan), ondansetron (Zofran) and metoclopramide (Reglan). Most important, remember that there are many other potentially deadly causes of N&V apart from the flu.
November 2009: EMS Magazine
Yara Popst Armando, Simone Grigoleto Schramm, Marina de Freitas Silva, Eunice Kazue Kano, Eunice Emiko Mori Koono, Valentina Porta, Cristina Helena dos Reis Serra
The purpose of this study was to evaluate bioequivalence of two commercial 8 mg tablet formulations of ondansetrona available in the Brazilian market. In this study, a simple, rapid, sensitive and selective liquid chromatography-tandem mass spectrometry method is described for the determination of ondansetron in human plasma samples. The method was validated over a concentration range of 2.5-60 ng/ml and used in a bioequivalence trial between orally disintegrating and conventional tablet ondansetron formulations, to assess its usefulness in this kind of study...
January 21, 2009: International Journal of Pharmaceutics
Mathew George, Nadeem Al-Duaij, Katherine A O'Donnell, Michael Wayne Shannon
INTRODUCTION: Ondansetron, an increasingly prescribed 5-HT(3) antagonist used in the management of nausea and vomiting of various etiologies, has a well-established safety profile in therapeutic use. However, little is known about its effects in the setting of an overdose. We describe the first case of severe toxicity in an infant who unintentionally ingested a large quantity of ondansetron. CASE REPORT: A 12-month-old infant who ingested seven to eight tablets of his mother's Zofran (ondansetron) ODT 8 mg rapidly developed obtundation and myoclonic movements...
December 2008: Clinical Toxicology
A U Lekmanov, B A Tkachenko, S G Suvorov
The efficiency of using various formulations of the antiemetic ondansetron to prevent postoperative nausea and vomiting (PONV) in the surgical treatment of postburn scars and deformities in children with a family history of PONV was compared. The patients were randomized into 4 representative groups. Preoperative administration of ondansetron (zofran) as lingual tablets was shown to be most effective. When the drug was used as syrup, PONV developed 2 times more frequently (PONV in 20% of the patients and 3 times more commonly when the drug was intravenously injected as jets during induction to anesthesia (PONV in 30% of the patients...
January 2008: Anesteziologiia i Reanimatologiia
(no author information available yet)
No abstract text is available yet for this article.
March 2007: FDA Consumer
R C C Poon, N Agnihotri, C Seymour, C Mothersill
Actual risk and risk management of exposure to ionizing radiation are among the most controversial areas in environmental health protection. Recent developments in radiobiology especially characterization of bystander effects have called into question established dogmas and are thought to cast doubt on the scientific basis of the risk assessment framework, leading to uncertainty for regulators and concern among affected populations. In this paper we test the hypothesis that small signaling molecules widely used throughout the animal kingdom for signaling stress or environmental change, such as 5-Hydroxytryptamine (5-HT, serotonin), l-DOPA, glycine or nicotine are involved in bystander signaling processes following ionizing radiation exposure...
October 2007: Environmental Research
Theresa Hartsell, Donlin Long, Jeffrey R Kirsch
Postoperative nausea and vomiting is a frequent complication of craniotomy. We evaluated the ability of intraoperative IV ondansetron followed by postoperative ondansetron in an orally disintegrating tablet formulation to reduce the frequency and severity of postoperative nausea and vomiting in a prospective, randomized, placebo-controlled double-blind trial of 60 patients undergoing acoustic neuroma resection. Each patient received intraoperative ondansetron (4 mg IV) or placebo 30 min before case end. Postoperatively, patients received ondansetron in an orally disintegrating tablet formulation (8 mg BID) or placebo twice a day for up to 72 h...
November 2005: Anesthesia and Analgesia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"